Savient Pharmaceuticals to Provide Business Update on November 7, 2005
November 01 2005 - 5:30PM
Business Wire
Savient Pharmaceuticals Inc. (NASDAQ: SVNTE), an emerging specialty
pharmaceuticals company focused on developing, manufacturing and
marketing novel therapeutic products for unmet medical needs,
announced today that it will issue a business update on Monday,
November 7, 2005. Christopher Clement, President and Chief
Executive Officer, will host a conference call on, November 7, 2005
at 11:00 a.m. EST. A live webcast of the conference call can be
accessed from the Webcast page under the News section of the
Company's website at www.savientpharma.com. A replay of the webcast
will be available on Savient Pharmaceuticals' website through
November 21, 2005. In addition, a telephonic replay will be
available through November 21, 2005. The replay numbers are (800)
642-1687 for domestic callers and (706) 645-9291 for international
callers. The replay access code is 1996046. About Savient
Pharmaceuticals, Inc. Based in East Brunswick, New Jersey, Savient
Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to developing, manufacturing and marketing novel
therapeutic products that address unmet medical needs. The
Company's lead product development candidate, Puricase(R), for the
treatment of refractory gout has reported positive Phase 1 and 2
clinical data. Savient's experienced management team is committed
to advancing its pipeline and expanding its product portfolio by
in-licensing late stage compounds and exploring co-promotion and
co-development opportunities that fit the Company's expertise in
specialty pharmaceuticals and initial focus in rheumatology. The
Company's operations also include a wholly-owned U.K. subsidiary,
Rosemont Pharmaceuticals Ltd., which develops, manufactures and
markets liquid formulations of prescription pharmaceutical
products. Rosemont's product portfolio includes over 90 liquid
formulations primarily targeting the geriatric population. Further
information on the Company can be accessed by visiting
www.savientpharma.com. Safe Harbor Statement This news release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934. All statements, other
than statements of historical facts, included in this report
regarding the Company's strategy, expected future financial
position, discovery and development of products, strategic
alliances, competitive position, plans and objectives of management
are forward-looking statements. Words such as "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "will" and other
similar expressions help identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements involve
substantial risks and uncertainties and are based on current
expectations, assumptions, estimates and projections about the
Company's business and the biopharmaceutical and specialty
pharmaceutical industries in which the Company operates. Such risks
and uncertainties include, but are not limited to, delisting of the
Company's common stock from The Nasdaq Stock Market, delay or
failure in developing Prosaptide(TM), Puricase(R) and other product
candidates; difficulties of expanding the Company's product
portfolio through in-licensing; introduction of generic competition
for Oxandrin(R); fluctuations in buying patterns of wholesalers;
potential future returns of Oxandrin or other products; our
continuing to incur substantial net losses for the foreseeable
future; difficulties in obtaining financing; potential development
of alternative technologies or more effective products by
competitors; reliance on third-parties to manufacture, market and
distribute many of the Company's products; economic, political and
other risks associated with foreign operations; risks of
maintaining protection for the Company's intellectual property;
risks of an adverse determination in on-going or future
intellectual property litigation; and risks associated with
stringent government regulation of the biopharmaceutical and
specialty pharmaceutical industries. The Company may not actually
achieve the plans, intentions or expectations disclosed in its
forward-looking statements, and you should not place undue reliance
on the Company's forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that the
Company makes. The Company's forward-looking statements do not
reflect the potential impact of any future acquisitions, mergers,
dispositions, joint ventures or investments that the Company may
make. The Company does not assume any obligation to update any
forward-looking statements.
Savient (NASDAQ:SVNTE)
Historical Stock Chart
From May 2024 to Jun 2024
Savient (NASDAQ:SVNTE)
Historical Stock Chart
From Jun 2023 to Jun 2024